<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03782532</url>
  </required_header>
  <id_info>
    <org_study_id>EFC13995</org_study_id>
    <secondary_id>U1111-1175-0772</secondary_id>
    <nct_id>NCT03782532</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the efficacy of dupilumab in patients with persistent asthma

      Secondary Objectives:

        -  To evaluate the safety and tolerability of dupilumab

        -  To evaluate the effect of dupilumab on improving patient reported outcomes including
           health related quality of life

        -  To evaluate dupilumab systemic exposure and immunogenicity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of study per patient is approximately 40 weeks, including 3 to 5 weeks of
      screening period, 24 weeks of treatment period and 12 weeks of post-treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pre-bronchodilator forced expiratory volume (FEV1)</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Absolute change from baseline in pre-bronchodilator FEV1 at Week 36</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of severe exacerbation events</measure>
    <time_frame>During the 24-week placebo-controlled treatment period</time_frame>
    <description>Annualized rate of severe exacerbation events during the 24-week placebo-controlled treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in pre-bronchodilator FEV1</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Percent change from baseline in pre-bronchodilator FEV1 at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of loss of asthma control (LOAC) event</measure>
    <time_frame>During the 24-week placebo-controlled treatment period</time_frame>
    <description>Annualized rate of LOAC event during the 24-week placebo-controlled treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of severe exacerbation events resulting in hospitalization or emergency room visit</measure>
    <time_frame>During the 24-week placebo-controlled treatment period</time_frame>
    <description>Annualized rate of severe exacerbation events resulting in hospitalization or emergency room visit during the 24-week placebo-controlled treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first severe exacerbation event</measure>
    <time_frame>During the 24-week placebo-controlled treatment period</time_frame>
    <description>Time to first severe exacerbation event during the 24-week placebo-controlled treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first LOAC</measure>
    <time_frame>During the 24-week placebo-controlled treatment period</time_frame>
    <description>Time to first LOAC during the 24-week placebo-controlled treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Asthma Control Questionnaire (ACQ)-5 score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline in ACQ-5 score at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ACQ-7 score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline in ACQ-7 score at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning/evening asthma symptom score (e-diary)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline at Week 24 in morning/evening asthma symptom score (e-diary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal awakenings (e-diary)</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Change from baseline at Week 24 in nocturnal awakenings (e-diary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of daily puffs of rescue medication</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline at Week 24 in use of daily puffs of rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) with Standardized Activities (≥12 years) (AQLQ+12)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline in AQLQ with Standardized Activities (≥12 years) (AQLQ+12) at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline in EQ-5D-5L at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events (AEs)</measure>
    <time_frame>Baseline to week 36</time_frame>
    <description>Number of participants with adverse events (AEs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">486</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients without oral corticosteroids (OCS) maintenance therapy, dose 1 of dupilumab administered once in 2 weeks (q2w) with loading dose of dupilumab, two times dose 1; for patients on OCS maintenance therapy, the dose will be dupilumab dose 2 q2w with loading dose 2 times dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for dupilumab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For patients without OCS maintenance therapy, the patients will take placebo matching to dupilumab dose 1 q2w with loading dose; for patients on OCS maintenance therapy, the patients will take placebo matching to dupilumab dose 2 q2w with loading dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab SAR231893</intervention_name>
    <description>Pharmaceutical form: Solution
Route of administration: Subcutaneous</description>
    <arm_group_label>Dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Solution
Route of administration: Subcutaneous</description>
    <arm_group_label>Placebo for dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asthma Controller Therapies (include prednisone/prednisolone)</intervention_name>
    <description>Pharmaceutical form: Aerosol, capsules, tablets, oral solution
Route of administration: Inhalation, oral</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_label>Placebo for dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asthma Reliever Therapies</intervention_name>
    <description>Pharmaceutical form: Nebulized, aerosol
Route of administration: Inhaled</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_label>Placebo for dupilumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Adults and adolescent patients (≥12 years of age) with a physician diagnosis of asthma
             for ≥12 months, based on the Global Initiative for Asthma 2017 Guidelines and the
             following criteria:

          -  Patients requiring a third controller for their asthma will be considered eligible for
             this study, and it should also be used for at least 3 months with a stable dose ≥1
             month prior to the screening visit (Visit 1).

          -  Patients requiring maintenance oral corticosteroids (OCS) with a stable dose ≤10
             mg/day prednisone or equivalent will be allowed; OCS should be used for at least 3
             months with a stable dose ≥1 month prior to the screening visit (Visit 1).

          -  Pre-bronchodilator FEV1 ≤ 80% of predicted normal for adults and ≤90% of predicted
             normal for adolescents at the screening visit and the randomization visit (Visits 1
             and 2), prior to randomization.

          -  Asthma Control Questionnaire 5-question version (ACQ-5) score ≥1.5 at the screening
             visit and the randomization visit (Visits 1 and 2), prior to randomization.

          -  For patients not requiring maintenance OCS, screening blood eosinophil count ≥150
             cells/μL or Fractional Exhaled Nitric Oxide (FENO) ≥25 parts per billion (ppb); for
             patients requiring maintenance OCS, there is no minimum requirement for blood
             eosinophil count and FENO level.

        Exclusion criteria:

          -  Patients &lt;12 years of age or the minimum legal age for adolescents in the country of
             the investigative site, whichever is higher (for those countries where local
             regulations permit enrollment of adults only, patient recruitment will be restricted
             to those who are ≥18 years of age).

          -  Weight is less than 30 kg at the screening visit (Visit 1) or the randomization visit
             (Visit 2).

          -  Chronic obstructive pulmonary disease or other lung diseases (eg, idiopathic pulmonary
             fibrosis) which may impair lung function.

          -  A patient who experiences a severe asthma exacerbation (defined as deterioration of
             asthma that results in emergency treatment, hospitalization due to asthma, treatment
             with systemic steroids, or treatment with systemic steroid at least twice the previous
             dose for patients on OCS maintenance) at any time from 1 month prior to the screening
             visit (Visit 1) up to and including the randomization visit (Visit 2).

          -  Evidence of lung disease(s) other than asthma, either clinical or imaging evidence
             (eg, chest X-ray, computed tomography, and magnetic resonance imaging) within 3 months
             prior to the screening visit (Visit 1) as per local standard of care.

          -  Current smoker or cessation of smoking within 6 months prior to the screening visit
             (Visit 1).

          -  Previous smoker with a smoking history &gt;10 pack-years.

          -  Comorbid disease that might interfere with the evaluation of investigational medicinal
             product (IMP).

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>1 then #</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 1560013</name>
      <address>
        <city>Baotou</city>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560016</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560029</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560015</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560009</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560010</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560030</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560053</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560025</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560004</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560001</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560045</name>
      <address>
        <city>Guangzhou</city>
        <zip>510150</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560032</name>
      <address>
        <city>Guiyang</city>
        <zip>550002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560019</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560007</name>
      <address>
        <city>Hangzhou</city>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560014</name>
      <address>
        <city>Hangzhou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560026</name>
      <address>
        <city>Hangzhou</city>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560043</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560038</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560044</name>
      <address>
        <city>Hohhot</city>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560008</name>
      <address>
        <city>Hohhot</city>
        <zip>010050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560022</name>
      <address>
        <city>Lanzhou</city>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560024</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560051</name>
      <address>
        <city>Nanjing</city>
        <zip>210005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560037</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560035</name>
      <address>
        <city>Pingxiang</city>
        <zip>337055</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560050</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560049</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560005</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560011</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560017</name>
      <address>
        <city>Shanghai</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560006</name>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560002</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560018</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560036</name>
      <address>
        <city>Shenyang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560012</name>
      <address>
        <city>Shenzhen</city>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560042</name>
      <address>
        <city>Shenzhen</city>
        <zip>518102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560003</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560041</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560031</name>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560048</name>
      <address>
        <city>Taiyuan</city>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560020</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560033</name>
      <address>
        <city>Urumchi</city>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560021</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560052</name>
      <address>
        <city>Wuhan</city>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560028</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560040</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560046</name>
      <address>
        <city>Xiamen</city>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560027</name>
      <address>
        <city>Xiangtan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560023</name>
      <address>
        <city>Xuzhou</city>
        <zip>221002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560047</name>
      <address>
        <city>Zhanjiang</city>
        <zip>524001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3560006</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3560002</name>
      <address>
        <city>Coimbatore</city>
        <zip>641045</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3560005</name>
      <address>
        <city>Jaipur</city>
        <zip>302023</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3560010</name>
      <address>
        <city>Kolkata</city>
        <zip>700107</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3560003</name>
      <address>
        <city>Nagpur</city>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3560001</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3560009</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3560007</name>
      <address>
        <city>Vellore</city>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560056</name>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

